Publications by authors named "Kenji Namba"

Claim this Profile
[
[Novel model of replicative Legionella pneumophila lung infection in DBA/2 mice].
Yoshinori Kashimoto, Yuichi Kurosaka, Yukie Karibe, Saori Uoyama, Kenji Namba

Jpn J Antibiot· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Therapeutic efficacy of levofloxacin against a model of replicable Legionella pneumophila lung infection in DBA/2 mice].
Yoshinori Kashimoto, Yuichi Kurosaka, Yukie Karibe, Saori Uoyama, Katsuko Fujikawa, Kenji Namba

Jpn J Antibiot· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of beta-1,6-glucan inhibitors on the invasion process of Candida albicans: potential mechanism of their in vivo efficacy.
Akihiro Kitamura, Saito Higuchi, Masato Hata, Katsuhiro Kawakami, Kumi Yoshida, Kenji Namba

Antimicrob Agents Chemother· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone.
Kazuki Hoshino, Kazue Inoue, Yoichi Murakami, Yuichi Kurosaka, Kenji Namba

Antimicrob Agents Chemother· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
Ken-Ichi Yoshida, Kiyoshi Nakayama, Masami Ohtsuka, Noriko Kuru, Yoshihiro Yokomizo, Kenji Namba

Bioorg Med Chem· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 6: exploration of aromatic substituents.
Ken-ichi Yoshida, Kiyoshi Nakayama, Yoshihiro Yokomizo, Masami Ohtsuka, Makoto Takemura, Kenji Namba

Bioorg Med Chem· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Development of antituberculous drugs: current status and future prospects].
Haruaki Tomioka, Kenji Namba

Kekkaku· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
Arvind M Dhople, Kenji Namba

Int J Antimicrob Agents· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.
Arvind M Dhople, Kenji Namba

J Infect Chemother· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative evaluation of the neuroprotective effects of hypothermia ranging from 34 degrees C to 31 degrees C on brain ischemia in gerbils and determination of the mechanism of neuroprotection.
Yoshimasa Takeda, Kenji Namba, Tomoyasu Higuchi, Shingo Hagioka, Ken Takata

Crit Care Med· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans.
Arvind M Dhople, Kenji Namba

J Antimicrob Chemother· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis